Welcome to our dedicated page for Cosmos Health SEC filings (Ticker: COSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cosmos Health Inc. (COSM) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, giving investors structured access to its official record as a Nasdaq Capital Market issuer. Cosmos Health describes itself as a diversified, vertically integrated global healthcare group, and its filings reflect activity in pharmaceuticals, nutraceuticals, manufacturing, distribution, telehealth and digital assets.
Key documents include annual reports on Form 10-K and quarterly reports on Form 10-Q, which present audited and interim financial statements, segment information tied to wholesale distribution, pharma manufacturing and branded products, as well as discussions of risk factors, liquidity and capital resources. Notifications such as the NT 10-Q filing explain delays in periodic reports and provide context on reporting timelines.
Cosmos Health also files numerous Current Reports on Form 8-K detailing material events. Recent 8-Ks cover topics such as record quarterly results, Nasdaq minimum bid price compliance notices, entry into a Securities Purchase Agreement for up to $300 million of senior secured convertible notes, the issuance of an initial $8 million note, governance and board changes, and shareholder approvals to increase authorized share capital and authorize a potential reverse stock split. These filings help investors track financing structures, capital allocation and corporate governance decisions.
Proxy materials like the DEF 14A definitive proxy statement provide information on director elections, executive compensation, equity incentive plans and shareholder proposals, including approvals related to the note financing and changes in authorized shares. Together with Form 4 insider transaction reports referenced in company news, these documents allow users to monitor ownership changes and board-level decisions.
On Stock Titan, COSM filings are updated in near real time as they are posted to EDGAR. AI-powered summaries highlight the main points of lengthy 10-K and 10-Q reports, explain complex financing terms in 8-Ks, and surface items such as bid price compliance, convertible note terms and voting outcomes. Users can quickly locate Forms 10-K, 10-Q, 8-K, DEF 14A and Form 4 filings, then rely on AI insights to understand how each filing may relate to Cosmos Health’s operations, balance sheet, governance and listing status.
Cosmos Health Inc. CEO Grigorios Siokas acquired 133,953 common shares at $0.5375 per share on January 6, 2026. The shares were issued under a Debt Exchange Agreement in which $72,000 of debt the company owed to Mr. Siokas was exchanged for stock at the fair market value of the common shares on that date.
After this transaction, Mr. Siokas beneficially owned 6,850,724 shares of Cosmos Health common stock in direct ownership. He is reported as a director, chief executive officer, and a 10% owner of the company.
COSMOS HEALTH INC. reported that Nasdaq notified the company on December 11, 2025 that it is not in compliance with the Nasdaq Listing Rule requiring a minimum bid price of $1.00 per share for 30 consecutive business days. The company now has 180 calendar days from December 11, 2025 to regain compliance by keeping its common stock closing bid price at or above $1.00 per share for at least 10 consecutive business days.
If the company does not otherwise regain compliance with this listing standard, it states that it intends to implement a reverse stock split to meet the rule. Nasdaq will also display an indicator with quotation information related to the company’s securities, signaling the current non-compliance status to the market.
Cosmos Health Inc. CEO Grigorios Siokas converted $70,000 of company debt into 168,472 shares of common stock on December 15, 2025. The shares, described as Exchange Shares under a Debt Exchange Agreement between Siokas and the company, were issued at $0.4155 per share, identified as the fair market value of the stock on that date.
After this transaction, Siokas directly beneficially owned 6,628,457 Cosmos Health common shares. He is listed as a director, chief executive officer, and a more than 10% owner of Cosmos Health Inc.
Cosmos Health Inc. (COSM) reported an insider transaction by Chief Executive Officer, director and 10% owner Grigorios Siokas. On 11/25/2025, Mr. Siokas acquired 55,732 shares of common stock at $0.628 per share through a debt-for-equity exchange.
Under a Debt Exchange Agreement between Mr. Siokas and the company, these Exchange Shares were issued in exchange for $35,000 of debt that Cosmos Health owed to him. Following this transaction, Mr. Siokas beneficially owns 6,383,625 shares of Cosmos Health common stock, held in direct ownership.
Cosmos Health Inc. (COSM) CEO, director and 10% owner Grigorios Siokas reported acquiring common stock through a debt-for-equity exchange. On 11/21/2025, he acquired 56,080 shares of common stock at $0.6776 per share, identified as Exchange Shares under a Debt Exchange Agreement between him and the company. The price reflects the fair market value of the stock on that date and was used to exchange $38,000 of debt the company owed to him. Following this transaction, he beneficially owned 6,327,893 shares of Cosmos Health common stock, held directly.
Cosmos Health Inc. (COSM) insider Grigorios Siokas increased his stake through a debt-for-equity exchange. On 11/20/2025, the CEO, director and 10% owner acquired 51,315 shares of common stock at $0.6236 per share. The shares were issued as "Exchange Shares" in satisfaction of $32,000 that the company owed to him under a debt exchange agreement, using the fair market value of the stock on that date.
After this transaction, Siokas beneficially owned 6,271,813 shares held directly. This was a non-cash transaction for the company, converting a payable to equity while increasing the CEO’s direct ownership.
Cosmos Health Inc. (COSM) disclosed that its Chief Executive Officer, director and 10% owner, Grigorios Siokas, acquired additional common shares through a debt-for-equity exchange. On November 19, 2025, he acquired 61,614 shares of common stock at $0.6492 per share, described as the fair market value of the stock on that date. The shares were issued in exchange for a total of $40,000 that the company owed to Mr. Siokas under a debt exchange agreement. Following this transaction, he beneficially owns 6,220,498 common shares directly.
Cosmos Health Inc. (COSM) filed a Form 8-K stating that on November 17, 2025 it issued a press release announcing its financial results for the quarter and nine months ended September 30, 2025. The press release is included as Exhibit 99.1 and provides the detailed financial figures and commentary. The company notes that the information in Items 2.02 and 7.01 and in Exhibit 99.1 is being furnished, not filed, under securities law, which limits certain legal liabilities and how the information may be incorporated into other filings.
Cosmos Health Inc. filed a replacement Form S-3 shelf registering up to $200,000,000 of common stock, preferred stock, warrants, units and subscription rights to be offered from time to time after effectiveness. The filing also includes a prospectus supplement for an at-the-market offering of up to $100,000,000 of common stock through A.G.P., which will earn a 3% commission on gross proceeds.
The company notes that, as of November 6, 2025, 34,919,920 shares of common stock were outstanding, with 26,274,546 held by non‑affiliates. Our common stock last closed at $0.67 on November 6, 2025, and trades on Nasdaq as “COSM.”
Unless otherwise indicated in a supplement, net proceeds are intended for the acquisition of crypto assets as a treasury asset and for general corporate purposes and working capital. Sales under the ATM may occur at market prices “from time to time,” subject to Securities Act Rule 415 and public float constraints.
Cosmos Health Inc. (COSM) reported that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement. Nasdaq notified the company that the closing bid price of its common stock was at least $1.00 per share for 18 consecutive business days, from September 22, 2025 to October 15, 2025, and the matter is now closed.
The update follows a prior notice on November 6, 2024 that COSM was below the $1.00 threshold for 30 consecutive business days. The company furnished a press release about the compliance status under Regulation FD.